Note: Upacicalcet is an investigational product candidate in the United States and subject to regulatory review and approval by the U.S. Food and Drug Administration (FDA).
Pathalys and LaunchTx leverage recently announced collaboration to accelerate enrollment for the upacicalcet development program. Research Triangle Park, North Carolina and Boston, Massachusetts, May 31, 2023 – Pathalys Pharma,
Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ: CG), led financings and was joined by Carlyle, OrbiMed,
RESEARCH TRIANGLE PARK, N.C., June 2, 2022 – Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range…
Research Triangle Park, N.C., April 8, 2022 – Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range
– Plans for Phase 3 Program Presented at National Kidney Foundation’s Annual Spring Clinical Meeting – Research Triangle Park, N.C., April 7, 2022 – Pathalys
– Executive Leadership Team Brings Diverse Skills and Broad Expertise to New Venture – RESEARCH TRIANGLE PARK, N.C., March 30, 2022 – Pathalys Pharma, Inc.,